Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$11.5M Buy
477,573
+238,366
+100% +$6.24M 0.11% 163
2026
Q1
$6.72M Sell
239,207
-777,456
-76% -$20.7M 0.09% 187
2025
Q4
$25.3M Buy
1,016,663
+667,120
+191% +$16.8M 0.29% 70
2025
Q3
$8.91M Buy
349,543
+1,528
+0.4% +$37.7K 0.11% 161
2025
Q2
$8.44M Sell
348,015
-38,396
-10% -$895K 0.12% 147
2025
Q1
$9.79M Sell
386,411
-14,602
-4% -$382K 0.15% 123
2024
Q4
$10.6M Sell
401,013
-446,373
-53% -$12.1M 0.14% 130
2024
Q3
$24.5M Buy
847,386
+378,518
+81% +$11M 0.37% 58
2024
Q2
$13.1M Buy
468,868
+22,040
+5% +$607K 0.54% 48
2024
Q1
$12.4M Sell
446,828
-13,153
-3% -$365K 0.49% 50
2023
Q4
$13.2M Buy
459,981
+7,325
+2% +$221K 0.29% 92
2023
Q3
$15M Buy
452,656
+75,747
+20% +$2.68M 0.33% 81
2023
Q2
$13.8M Buy
376,909
+79,672
+27% +$3.1M 0.33% 83
2023
Q1
$12.1M Sell
297,237
-17,533
-6% -$757K 0.31% 80
2022
Q4
$16.1M Buy
+314,770
New +$15.1M 0.46% 60

Other funds holding PFE

LBP AM's PFE Position: Q2 2026 in Review

LBP AM increased its Pfizer (PFE) stake by 100% in Q2 2026, buying an estimated $6.24M and bringing the position to 477,573 shares worth $11.5M. The position accounts for 0.11% of the portfolio, ranked #163.

LBP AM first reported a position in PFE in Q4 2022 and has held it in 15 quarters since. The position peaked at $25.3M in Q4 2025. 900 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • LBP AM held 477,573 shares of Pfizer worth $11.5M as of Q2 2026.
  • LBP AM bought 238,366 Pfizer shares in Q2 2026, an estimated $6.24M.
  • Pfizer made up 0.11% of LBP AM's portfolio in Q2 2026, its #163 holding.
  • LBP AM first reported a position in Pfizer in Q4 2022 and has held it in 15 quarters since.
  • LBP AM's Pfizer position peaked at $25.3M in Q4 2025.
  • 900 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on LBP AM's 13F filing for Q2 2026, filed 24 Jul 2026.